Shengdi Chen, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China
Featured articles
Articles
-
-
The microglial P2Y6 receptor as a therapeutic target for neurodegenerative diseases
-
Neurodegenerative disorders, metabolic icebergs, and mitohormesis
-
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
-
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease
-
Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation
-
Measles-mumps-rubella vaccination timing and autism among young african american boys: a reanalysis of CDC data
-
A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States
-
Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments
-
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology
Editor-in-Chief
Aims and Scope
Translational Neurodegeneration is an open access, peer-reviewed journal that covers research, therapeutics and education for all aspects of neurodegenerative diseases. By offering a high-visibility forum for new insights and discussions, Translational Neurodegeneration creates a novel interface between the fields of basic, translational, and clinical research. It includes Parkinson's disease and movement disorders, Alzheimer's disease and other dementias, motor neuron disease and other neurodegenerative diseases.
Affiliated with
Annual Journal Metrics
-
Citation Impact 2023
Journal Impact Factor: 10.8
5-year Journal Impact Factor: 11.6
Source Normalized Impact per Paper (SNIP): 2.374
SCImago Journal Rank (SJR): 3.371Speed 2023
Submission to first editorial decision (median days): 7
Submission to acceptance (median days): 111Usage 2023
Downloads: 767,289
Altmetric mentions: 3,389